NEI Podcast – Details, episodes & analysis

What are the primary barriers to clozapine utilization in the United States, and how do these barriers impact patient care? What are some common misconceptions or negative attitudes among prescribers regarding clozapine, and how can these be addressed? What are some effective strategies for improving the management of clozapine’s side effects to encourage its use? What strategies can be implemented to improve education and awareness about clozapine? 

Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs. 

Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of clozapine in psychiatry. 

Let’s listen to Part 3 of our theme: Underutilized Psychiatric Drugs. 

Subscribe to the NEI Podcast, so that you don’t miss another episode! 

Resources 

The Clozapine Handbook  

Clozapine titrations paper (see Supplementary Material):  

de Leon J et al. Pharmacopsychiatry 2022;55(2):73-86. 

FDA committees meeting to discuss reevaluation of the Clozapine REMS program (November 19, 2024): click here. 

Join Dr. Andy Cutler as he talks with the co-author of the winning poster from the 2023 NEI Congress Young Investigator Poster Competition, Dr. Richard Price. They discuss the objectives, design, and key findings of the poster titled, “Improved Mood and Weight Gain Mitigation Following Switch from Aripiprazole to Cariprazine.” They also discuss the potential implications of these findings and applications of cariprazine in psychiatry. 

Dr. Richard Price is an Assistant Professor of Clinical Psychiatry at Weill Cornell Medical College. Maxwell Zachary Price, the lead author of the winning poster, is a medical student at Hackensack Meridian School of Medicine. 

Learn about upcoming NEI Meetings at https://nei.global/meetings

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don’t Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Andrew Cutler interviews Dr. Joseph Goldberg on the management of metabolic side effects associated with antipsychotics.

 Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MET

 Learning Objectives: After completing this educational activity, you should be better able to:

• Differentiate antipsychotic medications based on risk for metabolic side effects
• Monitor patients for metabolic side effects
• Implement management strategies to address metabolic side effects

 Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 NEI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 A posttest minimum score of 70% is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics

Credit Types. The following are being offered for this activity:

• Nurse Practitioner (ANCC): contact hours
• Pharmacy (ACPE): application-based contact hours
• Physician (ACCME): AMA PRA Category 1 Credits ™
• Physician Assistant (AAPA): Category 1 CME credits
• Psychology (APA): CE credits
• Social Work (ASWB-ACE): ACE CE credits
• Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™

 Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

 Disclosures: All individuals in a position to influence or control content were required to disclose any relevant financial relationships, which were then mitigated prior to the activity being presented.

 Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Joseph F. Goldberg, MD  

Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY

Consultant/Advisor: BioXcel, Intra-Cellular, Lundbeck, Otsuka, Sunovion

Speakers Bureau: Allergan/Abbvie, Intra-Cellular, Sage, Sunovion

Royalties: American Psychiatric Publishing, Cambridge University Press

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

 The Planning Committee and Peer Reviewer have no financial relationships to disclose.

 Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

 Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

 Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.

 Released: December 22, 2021          CE credit expires: December 22, 2024

Can you explain how the same symptoms may cut across numerous psychiatric disorders and how the same treatment may be efficacious across psychiatric disorders? What areas in psychopharmacology remain the most challenging to treat and why do you think that is?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the future of psychopharmacology.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology?

Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology

Part 3: The Future of Psychopharmacology

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Who is Pear and what are prescription digital therapeutics? Why are PDTs so important to the continuum of care, especially when it comes to mental health? In this fascinating interview, Dr. Andrew Cutler interviews Dr. Corey McMann, the President and CEO of Pear Therapeutics about the importance of this technology in treating mental health.

Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.

What are some of the new FDA approvals for medications that happened this year? What did we learn about the association between ADHD and Alzheimer’s disease from a nationwide cohort study that was conducted? In this important and timely episode, Dr. Andrew Cutler addresses these questions and many more on the most interesting updates in psychopharmacology in 2021.

Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996.

Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials.

Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry.

Resources:

This Month in Psychopharmacology: https://www.neiglobal.com/Members/MonthInPsychopharmNew/tabid/508/Default.aspx

FDA Clears Technology to Aid in Concussion Diagnosis: https://www.neiglobal.com/Members/MonthInPsychopharmPost/tabid/509/Default.aspx?topic=20527

International League Against Epilepsy Society (AES): https://www.ilae.org/

What was the inspiration behind creating the Fifth Edition video series? What are your best learning strategies for studying psychopharmacology?

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the Fifth Edition Video Series and about the most effective learning strategies for psychopharmacology!

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology?

Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology

Part 3: The Future of Psychopharmacology

Subscribe to the NEI Podcast, so that you don’t miss another episode!